AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy

被引：0
作者：
Kagiava, A. [1 ,2 ]
Karaiskos, C. [1 ,2 ]
Lapathitis, G. [1 ,2 ]
Sargiannidou, I. [1 ,2 ]
Bosch, A. [3 ]
Kleopa, K. A. [1 ,2 ,4 ,5 ]
机构：
[1] Cyprus Inst Neurol & Genet, Dept Neurosci, Engomi, Cyprus
[2] Cyprus Sch Mol Med, Engomi, Cyprus
[3] Univ Autonoma Barcelona, Inst Neurosci, Dept Biochem & Mol Biol, Barcelona, Spain
[4] Cyprus Inst Neurol & Genet, Ctr Neuromuscular Disorders, Engomi, Cyprus
[5] Cyprus Sch Mol Med, Engomi, Cyprus
来源：
HUMAN GENE THERAPY | 2021年 / 32卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P305
引用
收藏
页码：A121 / A122
页数：2
相关论文
共 50 条
  • [21] Preclinical Safety and Efficacy of AAV9 Gene Replacement Therapy for SLC6A1 Disorder
    Shaffo, Frances
    Rioux, Matthew
    Chen, Xin
    Gray, Steven
    MOLECULAR THERAPY, 2020, 28 (04) : 317 - 317
  • [22] AAV9 Gene Therapy Synergizes with Hematopoietic Replacement to Prevent Major Neurological Defects in a Mouse Model of Krabbe Disease
    Marshall, Michael S.
    Jakubaskus, Benas
    Issa, Yazan
    Karumutil, Subha
    Sands, Mark S.
    Gray, Steven J.
    Bongarzone, Ernesto R.
    ANNALS OF NEUROLOGY, 2015, 78 : S108 - S108
  • [23] Intravenous AAV9 Based Gene Therapy Corrects a Mouse Model of Sandhoff Disease
    Walia, Jagdeep S.
    Bello, Alexander
    Altaleb, Naderah
    Kruck, Christa
    Hemming, Richard
    Kobinger, Gary P.
    Triggs-Raine, Barbara
    MOLECULAR THERAPY, 2013, 21 : S146 - S146
  • [24] Amyotrophic Lateral Sclerosis gene therapy using recombinant AAV9 vectors to silence the mutant SOD1 gene
    Biferi, M. G.
    Roda, M.
    Barkats, M.
    HUMAN GENE THERAPY, 2012, 23 (05) : A17 - A17
  • [25] Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy as a Treatment Strategy in Mouse Models of Gaucher Disease
    Du, Sichen
    Ou, Huayuan
    Cui, Renjie
    Jiang, Nan
    Zhang, Meiqin
    Li, Xiaorong
    Ma, Jing
    Zhang, Jin
    Ma, Duan
    HUMAN GENE THERAPY, 2019, 30 (02) : 155 - 167
  • [26] Gene therapy strategy for Amyotrophic Lateral Sclerosis using recombinant AAV9 vectors to silence the mutant SOD1 gene
    Biferi, Maria Grazia
    Cohen-Tannoudji, Mathilde
    Rode, Marianne
    Barkats, Martine
    HUMAN GENE THERAPY, 2012, 23 (10) : A127 - A127
  • [27] SCREENING FOR INTERACTIONS BETWEEN VIRALLY DELIVERED CX32 AND NEUROPATHY-ASSOCIATED MUTANTS: TOWARDS A GENE THERAPY FOR CMT1X
    Kyriakoudi, S.
    Sargiannidou, I
    Kagiava, A.
    Kleopa, K. A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 271 - 271
  • [28] Treatment of Glutaric Aciduria Type 1 (GA-1) by GCDH Gene Replacement Therapy via Intracerebroventricular AAV9 Delivery
    Guo, Lu
    Shen, Tingting
    Ling, Zhi
    Zhu, Xi
    Luo, Wenjing
    Li, Yuhuan
    Li, Zhikun
    Li, Wei
    Zhao, Xiaoping
    Tian, Shin-Shay
    MOLECULAR THERAPY, 2022, 30 (04) : 124 - 124
  • [29] Efficacy & Safety of AAV9-Mediated GDAP1 Gene Replacement Therapy in CMT4A Mice
    Sanli, Merve Emecen
    Dong, Thomas
    Jiji, Anjala
    Hu, Yuhui
    Gray, Steven J.
    Chen, Xin
    MOLECULAR THERAPY, 2024, 32 (04) : 781 - 782
  • [30] Recombinant AAV9 vectors to silence the mutant SOD1 gene in Amyotrophic Lateral Sclerosis
    Biferi, M. G.
    Cohen-Tannoudji, M.
    Roda, M.
    Barkats, M.
    HUMAN GENE THERAPY, 2013, 24 (12) : A117 - A117
12345